Sensei Biotherapeutics, Inc. 8-K

What Happened
Sensei Biotherapeutics, Inc. (SNSE) filed an 8‑K on April 16, 2026 disclosing that three current directors (Christopher W. Gerry, Thomas Ricks, Kristian Humer) submitted conditional resignations on April 10, 2026 effective two business days after the Company’s Annual Meeting on June 10, 2026, contingent on stockholder approval of two proposals: (1) a conversion that would issue Series B preferred shares into common stock representing more than 20% of outstanding shares and effect a Nasdaq-defined change of control, and (2) a charter amendment increasing authorized common shares from 12,500,000 to 300,000,000. The Board conditionally appointed Stephen M. Hahn, Saira Ramasastry, and Karen Vousden to the Board effective at that same contingent effective time. The Company also disclosed anticipated executive changes (if the proposals are approved): Anand Parikh to become CEO (current COO) and Brian Stephenson, Ph.D. to become CFO (current Head of Operations & Finance). The Company adopted a Severance and Change in Control Plan on April 10, 2026.

Key Details

• Conditional resignations tendered April 10, 2026; effective two business days after the June 10, 2026 Annual Meeting if stockholder proposals pass.
• Stockholder proposals: conversion of Series B preferred that would represent >20% of common stock and trigger a change of control under Nasdaq rules; amendment to increase authorized common shares from 12,500,000 to 300,000,000.
• Incoming directors: Stephen M. Hahn, Saira Ramasastry, Karen Vousden; expected committee placements noted in the filing.
• Severance & CIC Plan (adopted April 10, 2026): designated participants include Anand Parikh, Christopher Gerry, Josiah Craver. Standard severance: Parikh 12 months, Gerry 9 months, Craver 6 months (paid in installments + COBRA); CIC-period severance: Parikh 18 months, Gerry & Craver 12 months (lump sum + COBRA + full acceleration of time‑based equity). Enhanced CIC bonus multiples: Parikh 1.5x target bonus, Gerry & Craver 1.0x. Payments conditioned on signed release (within 60 days) and subject to clawback.

Why It Matters
These disclosures describe a potential near-term change in control and a planned overhaul of the board and senior management that are contingent on stockholder approval. Approval of the conversion and charter amendment would materially increase outstanding common shares (conversion >20%) and expand authorized shares dramatically (to 300M), which are material governance and capitalization events investors should watch. The new severance/change‑in‑control plan creates defined payout and equity‑acceleration protections for key executives that could lead to significant cash and equity expense in a change‑in‑control scenario. Investors should review the Company’s Preliminary Proxy Statement (filed April 16, 2026) for full details before the June 10, 2026 Annual Meeting.